甲磺酸伊马替尼对难治性Ph染色体阳性急性淋巴细胞白血病患者免疫功能及生存率的影响  

Effect of Imatinib Mesylate on Immune Function and Survival Rate in Patients with Refractory Ph Chromosome Positive Acute Lymphoblastic Leukemia

作　　者：金英[1] JIN Ying(Department of Hematology,Jiamusi Central Hospital,Jiamusi 154002,Heilongjiang,China)

机构地区：[1]佳木斯市中心医院血液内科,黑龙江佳木斯154002

出　　处：《医学信息》2022年第13期139-141,共3页Journal of Medical Information

摘　　要：目的探讨甲磺酸伊马替尼对难治性Ph染色体阳性急性淋巴细胞白血病患者的免疫功能及生存率的影响。方法选取我院2017年6月-2020年11月收治的难治性Ph染色体阳性急性淋巴细胞白血病患者72例,采用随机数表法随机分为对照组与联合治疗组,各36例。对照组患者予以常规化疗,联合治疗组在对照组基础上加用甲磺酸伊马替尼治疗。比较两组T细胞免疫功能、完全缓解(CR)率、生存(OS)时间、无复发生存(RFS)时间及不良反应发生情况。结果联合治疗组治疗后CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均高于对照组,差异有统计学意义(P<0.05);联合治疗组完全缓解率为88.89%、中位生存时间为30.63个月、中位无复发生存时间为25.12个月,均高于对照组的38.89%、11.62个月及9.64个月,差异有统计学意义(P<0.05);联合治疗组不良反应总发生率为16.67%,低于对照组的58.33%,差异有统计学意义(P<0.05)。结论甲磺酸伊马替尼用于治疗难治性Ph染色体阳性急性淋巴细胞白血病疾病能有效改善患者免疫功能,延长患者无复发生存时间和总生存时间,且用药安全性较高。Objective To investigate the effect of imatinib mesylate on immune function and survival rate in patients with refractory Ph chromosome positive acute lymphoblastic leukemia.Methods A total of 72 patients with refractory Ph chromosome positive acute lymphoblastic leukemia admitted to our hospital from June 2017 to November 2020 were randomly divided into control group and combined treatment group,with 36 cases in each group.Patients in the control group were treated with conventional chemotherapy,while patients in the combined treatment group were treated with imatinib mesylate on the basis of the control group.T cell immune function,complete remission(CR)rate,survival(OS)time,non-recurrence survival(RFS)time and incidence of adverse reactions were compared between the two groups.Results After treatment,the levels of CD3^(+),CD4^(+) and CD4^(+)/CD8^(+) in the combined treatment group were higher than those in the control group,and the difference was statistically significant(P<0.05).The complete remission rate,median survival time and median recurrence-free survival time of the combined treatment group were 88.89%,30.63 months and 25.12 months,which were higher than 38.89%,11.62 months and 9.64 months of the control group,and the differences were statistically significant(P<0.05).The total incidence of adverse reactions in the combined treatment group was 16.67%,which was lower than 58.33% in the control group,and the difference was statistically significant(P<0.05).Conclusion Imatinib mesylate for the treatment of refractory Ph chromosome positive acute lymphoblastic leukemia can effectively improve the immune function of patients,prolong the recurrence free survival time and overall survival time of patients,and the drug safety is high.

关 键 词：PH染色体阳性 急性淋巴细胞白血病 甲磺酸伊马替尼 免疫功能 总生存时间 

分 类 号：R733.71[医药卫生—肿瘤]